Literature DB >> 10558932

Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. District of Columbia Gay Cohort Study. Multicenter Hemophilia Cohort Study.

E A Engels1, P S Rosenberg, R J Biggar.   

Abstract

Zoster is an important clinical problem for human immunodeficiency virus type 1 (HIV)-infected patients. Risk factors for zoster and trends in incidence in HIV-infected hemophiliacs and homosexual men (n=1218) were examined. From 1984 to 1997, 174 zoster cases were identified (average yearly incidence, 2.5%). Prior zoster episodes were associated with increased risk for a subsequent episode (relative risk [RR], 4.30; 95% confidence interval [CI], 3.11-5.95). Among hemophiliacs, children and adolescents had the highest zoster risk, and zoster risk declined with age (RR, 0.80 per decade; 95% CI, 0.68-0.93). These findings suggest that HIV-infected persons do not produce or maintain adequate booster responses after varicella zoster virus exposure. Zoster risk was relatively constant when CD4 cell counts >200 cells/mm3 but increased steeply below this level. During the 14 years of follow-up, zoster incidence declined 9% per year. This trend occurred despite decreasing CD4 cell counts and was unexplained by zidovudine or acyclovir use.

Entities:  

Mesh:

Year:  1999        PMID: 10558932     DOI: 10.1086/315146

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.

Authors:  Shih Hann Su; Valérie Martel-Laferrière; Annie-Claude Labbé; David R Snydman; David Kent; Michel Laverdière; Claire Béliveau; Tanya Logvinenko; Sandra Cohen; Silvy Lachance; Thomas Kiss; Jean Roy
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-25       Impact factor: 5.742

2.  Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Authors:  Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox
Journal:  Int J Infect Dis       Date:  2014-03-25       Impact factor: 3.623

Review 3.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

4.  Varicella zoster virus vasculopathy: analysis of virus-infected arteries.

Authors:  M A Nagel; I Traktinskiy; Y Azarkh; B Kleinschmidt-DeMasters; T Hedley-Whyte; A Russman; E M VanEgmond; K Stenmark; M Frid; R Mahalingam; M Wellish; A Choe; R Cordery-Cotter; R J Cohrs; D Gilden
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

5.  Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Varicella-zoster virus reactivation during acute enterovirus infection is associated with CD8 lymphocytopenia.

Authors:  John K Chia; Andrew A Chia
Journal:  BMJ Case Rep       Date:  2009-03-05

7.  The incidence of herpes zoster in a United States administrative database.

Authors:  Ralph P Insinga; Robbin F Itzler; James M Pellissier; Patricia Saddier; Alexander A Nikas
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

8.  Herpes Zoster and Risk of Cancer in the Elderly U.S. Population.

Authors:  Parag Mahale; Elizabeth L Yanik; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

9.  Disseminated herpes zoster with increased CD4 counts in 3 HIV-infected patients.

Authors:  Pooja Lidhoo; Patrick Unemori; Kieron S Leslie; Toby Maurer
Journal:  J Am Acad Dermatol       Date:  2009-08       Impact factor: 11.527

10.  Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.

Authors:  Charlene M McShane; Liam J Murray; Eric A Engels; Ola Landgren; Lesley A Anderson
Journal:  Int J Cancer       Date:  2013-10-12       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.